Protease-activated receptor 1 drives and maintains ductal cell fates in the premalignant pancreas and ductal adenocarcinoma.

Autor: Tekin C; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, The Netherlands.; Laboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., Scicluna BP; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, The Netherlands., Lodestijn SC; Laboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., Shi K; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, The Netherlands., Bijlsma MF; Laboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., Spek CA; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, The Netherlands.; Laboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.
Jazyk: angličtina
Zdroj: Molecular oncology [Mol Oncol] 2021 Nov; Vol. 15 (11), pp. 3091-3108. Date of Electronic Publication: 2021 May 14.
DOI: 10.1002/1878-0261.12971
Abstrakt: Pancreatic acinar cells have high plasticity and can transdifferentiate into ductal-like cells. This acinar-to-ductal metaplasia (ADM) contributes to tissue maintenance but may also contribute to the premalignant transformation that can eventually progress to pancreatic ductal adenocarcinoma (PDAC). Macrophages are key players in ADM, and macrophage-secreted matrix metalloproteinase (MMP)-9 induces ADM through yet unknown mechanisms. As we previously identified MMP9 as a novel agonist of protease-activated receptor 1 (PAR1), a receptor that is known to orchestrate the cross-talk between macrophages and tumor cells in PDAC, we here assessed the contribution of PAR1 to pancreatic cell fates. We found that genetic deficiency for PAR1 increases acinar gene expression programs in the healthy pancreas and that PAR1 deficiency limits ductal transdifferentiation in experimental systems for ADM. Moreover, PAR1 silencing in PDAC cells increases acinar marker expression. Changes in PDAC cell lines were associated with a downregulation of known Myc-target genes, and Myc inhibition mimics PAR1 deficiency in enhancing acinar programs in healthy organoids and PDAC cells. Overall, we identify the PAR1-Myc axis as a driver of ductal cell fates in premalignant pancreas and PDAC. Moreover, we show that cellular plasticity is not unique to acinar cells and that ductal regeneration into acinar-like cells is possible even in the context of oncogenic KRAS activation.
(© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
Databáze: MEDLINE
Externí odkaz: